{"analyses":[{"ciLowerLimit":"0.7","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.4","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.4865","pValueComment":"P Value is 1-sided","paramType":"Odds Ratio (OR)","paramValue":"0.95","statisticalComment":"exact CMH Chi-square statistic, adjusting for randomization stratification factor as per IRT.","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.7","upperLimit":"45.8","value":"39.6"},{"groupId":"OG001","lowerLimit":"34.8","upperLimit":"46.9","value":"40.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"265"}],"units":"Participants"}],"description":"FACIT-Fatigue score is a 13-item questionnaire designed to assess fatigue in cancer participants. All items use a 5-point scale ranging from 0 to 4 (0=Not at All to 4=Very Much). The total score ranges from 0 to 52 with higher values representing better quality of life. The responder is defined as having 3 points improvement from baseline confirmed by a second improvement of 3 points at any time, regardless of preceding worsening. A participant who could not improve was considered as a non-responder.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were randomized to sabatolimab plus Azacitidine","id":"OG000","title":"Sabatolimab (MBG453) + Azacitidine"},{"description":"Participants were randomized to placebo plus Azacitidine","id":"OG001","title":"Placebo + Azacitidine"}],"paramType":"NUMBER","populationDescription":"FAS comprised of all participants to whom study treatment had been assigned by randomization.","reportingStatus":"POSTED","timeFrame":"up to approx. 52 months","title":"Key Secondary Endpoint 3: Percentage of Participants With at Least 3 Point Confirmed Improvement From Baseline in FACIT-fatigue Scores","type":"SECONDARY","unitOfMeasure":"Percentage of participants with response"}